Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Carson

Showing results (331-340 of 360) with videos related to

Pageof 36
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 14, 2020
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PETAdam P Mecca, Ming-Kai Chen, Ryan S O'Dell, et al.
NPJ Parkinson'S Disease|February 24, 2024
Synaptic loss and its association with symptom severity in Parkinson's diseaseSophie E Holmes, Praveen Honhar, Sule Tinaz, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|May 17, 2020
Feasibility study of PET dynamic imaging of [<sup>18</sup>F]DHMT for quantification of reactive oxygen species in the myocardium of large animalsJing Wu, Nabil E Boutagy, Zhengxin Cai, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2025
Network-based Molecular Constraints on <i>in vivo</i> Synaptic Density Alterations in SchizophreniaSidhant Chopra, Patrick D Worhunsky, Mika Naganawa, et al.
NPJ Parkinson'S Disease|March 13, 2024
Author Correction: Synaptic loss and its association with symptom severity in Parkinson's diseaseSophie E Holmes, Praveen Honhar, Sule Tinaz, et al.
EJNMMI Research|March 4, 2022
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [<sup>11</sup>C]PF-06809247 in non-human primatesRyosuke Arakawa, Akihiro Takano, Sangram Nag, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 24, 2021
Comparison of [<sup>11</sup>C]UCB-J and [<sup>18</sup>F]FDG PET in Alzheimer's disease: A tracer kinetic modeling studyMing-Kai Chen, Adam P Mecca, Mika Naganawa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2022
Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [<sup>11</sup> C]UCB-JAdam P Mecca, Ryan S O'Dell, Emily S Sharp, et al.
Science Translational Medicine|November 1, 2023
Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastomaMinsoo Khang, Ju Hyun Lee, Teresa Lee, et al.
Molecular Psychiatry|June 25, 2026
Widespread synaptic density loss in schizophrenia follows molecular and network architectureSidhant Chopra, Patrick D Worhunsky, Mika Naganawa, et al.
Pageof 36

Showing results (331-340 of 360) with videos related to

Sort By:
Pageof 36
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 14, 2020
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PETAdam P Mecca, Ming-Kai Chen, Ryan S O'Dell, et al.
NPJ Parkinson'S Disease|February 24, 2024
Synaptic loss and its association with symptom severity in Parkinson's diseaseSophie E Holmes, Praveen Honhar, Sule Tinaz, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|May 17, 2020
Feasibility study of PET dynamic imaging of [<sup>18</sup>F]DHMT for quantification of reactive oxygen species in the myocardium of large animalsJing Wu, Nabil E Boutagy, Zhengxin Cai, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2025
Network-based Molecular Constraints on <i>in vivo</i> Synaptic Density Alterations in SchizophreniaSidhant Chopra, Patrick D Worhunsky, Mika Naganawa, et al.
NPJ Parkinson'S Disease|March 13, 2024
Author Correction: Synaptic loss and its association with symptom severity in Parkinson's diseaseSophie E Holmes, Praveen Honhar, Sule Tinaz, et al.
EJNMMI Research|March 4, 2022
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [<sup>11</sup>C]PF-06809247 in non-human primatesRyosuke Arakawa, Akihiro Takano, Sangram Nag, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 24, 2021
Comparison of [<sup>11</sup>C]UCB-J and [<sup>18</sup>F]FDG PET in Alzheimer's disease: A tracer kinetic modeling studyMing-Kai Chen, Adam P Mecca, Mika Naganawa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2022
Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [<sup>11</sup> C]UCB-JAdam P Mecca, Ryan S O'Dell, Emily S Sharp, et al.
Science Translational Medicine|November 1, 2023
Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastomaMinsoo Khang, Ju Hyun Lee, Teresa Lee, et al.
Molecular Psychiatry|June 25, 2026
Widespread synaptic density loss in schizophrenia follows molecular and network architectureSidhant Chopra, Patrick D Worhunsky, Mika Naganawa, et al.
Pageof 36